enGene Therapeutics ENGN Cash Flow Statement (2023-2026)

NASDAQ ENGN
$2.00 +0.05 (+2.56%)
At close: Sep 30, 2026 · 4:00 PM EDT
Reported Financials

enGene Therapeutics Quarterly Cash Flow Statement

Periods 15 quarters
Latest Jul 2026

enGene Therapeutics reported cash from operations of -$18.95M and free cash flow of -$18.95M for the quarter ended Jul 2026, up 26.1% year over year. This cash flow statement covers 15 quarters of results from Jan 2023 through Jul 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026 Jul2026
Operating Activities
Net Income -7.42M-5.28M-4.72M-82.50M-10.71M-14.98M-14.15M-15.30M-24.62M-25.82M-28.99M-37.88M-29.75M-30.23M-32.50M
Depreciation and Depletion 0.05M0.04M0.04M0.05M0.08M0.08M0.08M0.08M0.10M0.11M0.13M0.17M0.19M0.18M0.18M
Share-based Compensation 0.02M0.04M0.04M3.35M0.29M1.92M1.46M1.66M1.81M2.65M2.58M2.61M2.80M4.14M7.81M
Cash from Operations -6.22M-4.44M-7.30M-6.78M-7.37M-14.16M-7.18M-19.57M-25.70M-22.95M-25.63M-24.96M-28.90M-30.50M-18.95M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization 0.05M0.04M0.04M0.07M0.08M0.10M0.10M0.10M0.10M0.10M0.10M0.20M0.19M0.20M0.10M
Change in Working Capital
Change in Account Payables 0.83M1.22M-1.08M-0.59M0.22M-0.91M2.61M-1.45M1.13M-0.97M0.82M3.97M-4.27M-0.62M0.74M
Change in Accured Expenses -1.82M-0.45M0.17M2.97M2.15M0.41M3.20M-0.54M-3.88M3.92M-1.06M4.15M4.39M-2.48M5.04M
Other Working Capital Changes 0.06M0.13M0.61M-0.05M1.27M0.79M1.59M3.92M-0.42M1.77M-1.31M-2.03M2.42M1.58M-0.10M
Investing Activities
Capital Expenditures 0.01M0.01M0.16M0.14M0.51M0.18M0.00M0.24M0.30M0.04M0.70M0.44M0.15M0.10M
Cash from Investing Activities -0.01M-0.01M-0.16M-0.14M-0.51M-0.18M-0.00M-125.27M-84.96M17.95M1.38M40.50M-126.30M23.64M30.12M
Financing Activities
Other financing activities 0.44M0.14M0.61M-0.07M
Debt Issuance and Repayment
Long-Term Debt Issuances 30.00M22.50M25.00M
Change in Capital Stock
Net Equity Issued and Repurchased 56.88M60.15M0.00M0.20M0.03M1.99M126.25M-103.00M
Misc.
Cash from Financing Activities -0.01M7.76M27.55M50.84M12.00M193.50M0.05M60.16M0.00M0.20M-0.67M1.99M141.66M0.07M0.02M
Exchange Rate Effect 0.00M0.00M0.00M0.00M
Change in Cash -6.25M3.31M20.10M43.93M4.12M179.16M-7.13M-84.67M-110.66M-4.80M-24.92M17.53M-13.54M-6.79M11.20M
Free Cash Flow -6.24M-4.45M-7.46M-6.91M-7.88M-14.34M-7.18M-19.81M-26.00M-22.99M-26.34M-25.40M-29.06M-30.60M-18.95M
Net Cash Flow -6.25M3.31M20.10M43.93M4.12M179.16M-7.13M-84.67M-110.66M-4.80M-24.92M17.53M-13.54M-6.79M11.20M

enGene Therapeutics Cash Flow Statement API

Pull enGene Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ENGN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY